Analysts Set Geron Co. (NASDAQ:GERN) Target Price at $7.05

Geron Co. (NASDAQ:GERN) has received an average rating of “Buy” from the eleven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.05.

Several equities research analysts have recently issued reports on GERN shares. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright initiated coverage on Geron in a research note on Tuesday, November 5th. They issued a “buy” rating and a $8.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Geron in a research report on Friday, August 9th. StockNews.com raised Geron to a “sell” rating in a research report on Monday, August 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Geron in a research report on Thursday, August 8th.

Institutional Investors Weigh In On Geron

A number of hedge funds and other institutional investors have recently modified their holdings of GERN. National Bank of Canada FI increased its position in Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 6,000 shares during the period. Crewe Advisors LLC increased its holdings in shares of Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 8,700 shares during the period. Kingsview Wealth Management LLC acquired a new stake in shares of Geron in the first quarter valued at approximately $34,000. American Trust bought a new stake in shares of Geron in the first quarter valued at approximately $38,000. Finally, Rovin Capital UT ADV acquired a new stake in Geron during the third quarter worth approximately $62,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Stock Down 3.1 %

Shares of NASDAQ:GERN opened at $4.12 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -12.88 and a beta of 0.52. The company has a 50 day moving average of $4.30 and a 200-day moving average of $4.32. Geron has a one year low of $1.64 and a one year high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.10% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same period in the prior year, the business posted ($0.08) EPS. Geron’s revenue was up 17138.4% on a year-over-year basis. On average, sell-side analysts forecast that Geron will post -0.34 earnings per share for the current year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.